Patriot Scientific Corporation and Mosaic ImmunoEngineering Inc. Enter into Definitive Merger Agreement

Author's Avatar
Aug 24, 2020
Article's Main Image

CARLSBAD and NOVATO, CA / ACCESSWIRE / August 24, 2020 / Patriot Scientific Corporation (the "Company" or "Patriot") (OTC PINK:PTSC) and Mosaic ImmunoEngineering Inc., ("Mosaic") announced today that they have entered into a definitive agreement under which a wholly-owned subsidiary of Patriot will merge with Mosaic through the issuance of convertible preferred stock. The merged company will focus on advancing its immunotherapy pipeline of products including intra-tumoral immunotherapy of cancer and its modular vaccine platform.